EGFR and non-small cell lung carcinoma: In 2004, activating EGFR mutations were first identified in NSCLC and were characterized as oncogenic mutations that were shown to confer a more favourable prognosis and predict a greater sensitivity to EGFR TKIs [3,4,5].